Zoldonrasib
The first drug aimed specifically at KRAS G12D, the single most common mutation in pancreatic cancer. Early combination data in 2026 showed half of previously treated patients responding.
Revolution Medicines' covalent tri-complex inhibitor of KRAS G12D(ON). Breakthrough Therapy designation in G12D NSCLC (2025). At ESMO GI 2026, zoldonrasib plus daraxonrasib in previously treated RAS G12D metastatic PDAC (n=60, cutoff 9 Feb 2026): ORR 50% and DCR 97% in second line, median PFS 9.6 months; grade ≥3 treatment-related events 35% (rash, anaemia, stomatitis). First-line combination with gemcitabine/nab-paclitaxel showed high response rates and ctDNA clearance. Phase 3 planning underway.
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Zoldonrasib" OR ABSTRACT:"Zoldonrasib" OR TITLE:"RMC-9805" OR ABSTRACT:"RMC-9805") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Zoldonrasib, not a curated reading list.
Pages like this
not linked directly; found by shared links- ProductElironrasib
Shares Revolution Medicines, KRAS & RAS inhibitors, RAS / RAF / MEK / ERK (MAPK), KRAS.
- TrialRASolute 302
Shares RAS(ON) inhibitors to convert unresectable pancreatic cancer to resectable, Daraxonrasib, KRAS & RAS inhibitors, KRAS.
- CompanyQuanta Therapeutics
Shares Daraxonrasib, KRAS & RAS inhibitors, RAS / RAF / MEK / ERK (MAPK), KRAS.
- IdeaCovalent chemistry for the RAS mutations that still have no drug
Shares Revolution Medicines, Daraxonrasib, KRAS & RAS inhibitors, KRAS.
- ProductMRTX1133
Shares KRAS & RAS inhibitors, RAS / RAF / MEK / ERK (MAPK), KRAS, The undruggable drivers.
- RoadmapKRAS roadmap: undruggable → G12C → pan-RAS
Shares Revolution Medicines, Daraxonrasib, KRAS & RAS inhibitors, KRAS.
- CompanyFrontier Medicines
Shares KRAS & RAS inhibitors, RAS / RAF / MEK / ERK (MAPK), KRAS, The undruggable drivers.
- IdeaOff-the-shelf KRAS vaccines after pancreatic cancer surgery
Shares Daraxonrasib, KRAS & RAS inhibitors, KRAS, The undruggable drivers.